Regulation
The UK position, the borderline products question, human tissue law, and why jurisdictions diverge.
The UK position on exosome products, stated carefully
What can and cannot be said about the regulatory status of exosome products in the UK, which framework applies, and where the position is genuinely unsettled.
Topical after microneedling is a different question
Why applying a preparation to deliberately breached skin sits awkwardly between topical use and administration, and what is settled versus unsettled.
Borderline products and the MHRA
How the medicines definition works through presentation and function, why marketing claims can change a product's classification, and how to apply the test yourself.
Human tissue considerations
What engages human tissue law when a product derives from human cells, and the cosmetics restriction on materials of human origin.
Why jurisdictions diverge
How the same product can be lawful in one country and not in another without either regulator being wrong, and why availability abroad proves nothing.
Advertising claims and the ASA
How advertising rules apply to aesthetic claims, the substantiation requirement, and why a claim that cannot be evidenced should not be made.
The science briefing
One email a fortnight. What was published in extracellular vesicle and regenerative aesthetics research, what it actually showed, and which claims moved on our grading scale. Written for people who read the methods section.
No spam, unsubscribe in one click. We never pass your address to a third party. See privacy.
Sponsor slot Each issue carries one labelled sponsor line at the foot. Sponsorship buys that line and nothing else. It cannot influence an evidence grade, a correction, or whether a claim is covered. Rate card and refusals.